Retatrutide in Las Vegas
A plain-English, physician-reviewed guide to retatrutide — how the triple-agonist works, what the Phase 3 trials showed, where the 2026 FDA-approval outlook stands, and how to actually access care in Las Vegas. Questions? Ask Dr. Kamen at an $88 evaluation.
Medically reviewed by Charles Kamen, MD, board-certified neurologist ·
Retatrutide is one of the most talked-about names in metabolic medicine — a next-generation triple-receptor agonist that targets the GLP-1, GIP, and glucagon pathways. In published clinical trials, this class has been associated with some of the largest weight-loss reductions ever seen in obesity research. It is also, importantly, still investigational and not FDA-approved.
That distinction matters. FDA-approved medications like semaglutide and tirzepatide can be prescribed today after a medical evaluation. Retatrutide cannot be dispensed as a standard prescription while it remains in clinical development — and any product sold online as “research use only” retatrutide is not made or tested for human use. We are a physician practice, not a medication retailer, and the honest answer about where retatrutide stands is one Dr. Kamen will give you in person.
This page is general medical information for people researching retatrutide in Las Vegas, Henderson, and across Nevada. For physician-supervised, FDA-approved medical weight loss in Las Vegas, care starts with an evaluation — in person at our clinic at Eastern Avenue and the 215, or by secure telehealth for Nevada residents.
Retatrutide at a Glance
Investigational — in Phase 3 trials, not yet FDA-approved or available as a standard prescription
A triple-receptor agonist: GLP-1, GIP, and glucagon pathways (one more than tirzepatide)
Phase 3 trials report average weight loss approaching ~28–30% in adults with obesity
Avoid "research use only" online retatrutide — not manufactured or tested for human use
FDA-approved alternatives (semaglutide, tirzepatide) are available now after evaluation
Approval possible in 2026 or later — not guaranteed; bring your questions to a board-certified MD
How Retatrutide Works
Retatrutide is a triple-receptor agonist. It activates GLP-1 and GIP — incretin hormones your body already releases after eating that regulate insulin, slow stomach emptying, and signal fullness to the brain — plus the glucagon receptor, which influences energy expenditure and liver fat. That third pathway is the key difference from tirzepatide (a dual GIP/GLP-1 agonist) and semaglutide (a single-pathway GLP-1 agonist), and the reason the triple-agonist class is being studied so closely.
Because it affects appetite, gastric emptying, insulin regulation, and energy balance at once, retatrutide is a serious investigational drug — not something to order from a pop-up website. Any decision about weight-loss therapy belongs with a physician after an evaluation, not a checkout cart.
What the Phase 3 Trials Showed
Retatrutide is being studied in an eight-trial Phase 3 program (called TRIUMPH) across more than 5,800 participants. The headline results so far are among the strongest ever reported for an obesity medication — but they are trial averages, not individual results, and the drug remains investigational and not FDA-approved.
| Trial result | Average weight loss | Context |
|---|---|---|
| TRIUMPH-1 (obesity, no diabetes) — highest dose | ~28.3% at 80 weeks (≈70 lbs) | Reaching ~30.3% at 104 weeks |
| TRIUMPH-1 — share losing ≥30% | ~45% of participants | At the highest studied dose |
| TRIUMPH-4 (obesity + knee osteoarthritis) | ~28.7% at 68 weeks | Also reduced OA-related pain |
For comparison, FDA-approved GLP-1/GIP medications in published trials average roughly ~15% (semaglutide) and ~20–22.5% (tirzepatide) weight loss. Individual results vary widely and are not guaranteed.
When Will Retatrutide Be FDA-Approved? (2026 Outlook)
Retatrutide is not approved yet. The Phase 3 TRIUMPH program is the pivotal step toward a potential regulatory filing, and major trial readouts have been reported through 2025–2026. If a filing is accepted and the review succeeds, approval is possible in 2026 or later — but this is not guaranteed, and timelines in drug development routinely shift.
| Stage | Status | What it means |
|---|---|---|
| Phase 2 | Published (NEJM, 2023) | Established the triple-agonist weight-loss signal |
| Phase 3 (TRIUMPH) | 8 trials, 5,800+ people; readouts 2025–26 | Pivotal data for a potential FDA filing |
| Regulatory filing | Expected after the program completes | Developer submits for approval review |
| FDA decision | Possible 2026 or later — not guaranteed | If approved, would become a prescription — not before |
Until retatrutide is approved, no clinic — including ours — can dispense it as a prescription. The right move today is an evaluation with Dr. Kamen: start an FDA-approved GLP-1/GIP medication if it fits you, and get an honest, current read on where retatrutide stands for when it does become available.
Retatrutide vs. Tirzepatide vs. Semaglutide
| Medication | Receptor targets | FDA status | Available now? |
|---|---|---|---|
| Semaglutide | GLP-1 | FDA-approved | Yes — after evaluation |
| Tirzepatide | GLP-1 + GIP | FDA-approved | Yes — after evaluation |
| Retatrutide | GLP-1 + GIP + glucagon | Investigational (not approved) | No — ask Dr. Kamen |
Where to Buy Retatrutide in Las Vegas
The honest answer: you can’t. Retatrutide is investigational and not FDA-approved, so it is not available as a standard prescription in Las Vegas, Henderson, or anywhere else. Any website offering “research use only” retatrutide for human use is selling a product that was never manufactured, tested, or labeled for people — and we strongly recommend against it.
What you can do today is start physician-guided care: FDA-approved GLP-1/GIP medications like tirzepatide and semaglutide are available right now after an evaluation, and you can ask Dr. Kamen in person about retatrutide and its current status. Care begins with a $88 evaluation — in person at our southeast Las Vegas clinic or by secure telehealth anywhere in Nevada.
Retatrutide Cost & Access in Las Vegas
Retatrutide itself has no legal price as a prescription — because it is not approved and cannot be dispensed. What does have a price is physician-guided care:
- $88 evaluation — with Dr. Kamen, applied toward your plan if you continue.
- Baseline labs — ordered as indicated; cost depends on your panel and coverage.
- FDA-approved GLP-1/GIP medication at pharmacy pass-through cost, no markup — billed at exactly what the licensed US pharmacy charges, based on your dose.
Your real monthly number is reviewed with you before you pay anything beyond the evaluation. If a different option fits your situation and budget better, that is what gets recommended — never a hidden subscription.
Retatrutide in Las Vegas — FAQ
What is retatrutide?
Retatrutide is an investigational triple-receptor agonist being studied for weight management — it acts on the GLP-1, GIP, and glucagon pathways, one more than current dual-agonist medications like tirzepatide. In published clinical trials this class has been associated with significant reductions in body weight and visceral fat. It is still in clinical development and is not yet FDA-approved.
Is retatrutide FDA-approved or legal?
Retatrutide is not FDA-approved — it is an investigational drug still in clinical trials and is not available as a standard prescription medication the way semaglutide and tirzepatide are. Its regulatory status can change as trials progress; the most current answer for your situation is one a licensed physician can give you directly.
Where can I buy retatrutide in Las Vegas?
You cannot buy retatrutide as a normal prescription anywhere — including Las Vegas — because it is investigational and not FDA-approved. Products marketed online as "research use only" retatrutide are not manufactured, tested, or labeled for human use, and we strongly recommend against them. What you can do today is book a physician evaluation: FDA-approved GLP-1/GIP medications are available after evaluation, and you can ask Dr. Kamen about retatrutide and its current status in person.
When will retatrutide be FDA-approved?
Retatrutide is not approved yet. Its Phase 3 program (called TRIUMPH) includes eight pivotal trials across more than 5,800 participants, with major readouts reported through 2025–2026. A regulatory filing could follow once the program completes, and — if that filing is accepted and succeeds — approval would be possible in 2026 or later. This is not guaranteed, and the timeline can shift. The honest, current answer is the one a physician gives you at your evaluation.
How much weight do people lose on retatrutide?
In the Phase 3 TRIUMPH-1 trial in adults with obesity (without type 2 diabetes), the highest studied dose was associated with an average weight loss of about 28.3% at 80 weeks — roughly 70 pounds — reaching about 30.3% at 104 weeks, and about 45% of participants lost at least 30% of their body weight. A separate trial in obesity with knee osteoarthritis reported about 28.7% average loss at 68 weeks. These are trial averages, not individual results or guarantees, and retatrutide remains investigational.
How is retatrutide different from tirzepatide and semaglutide?
Retatrutide adds a third receptor pathway (glucagon) on top of the GLP-1 and GIP pathways targeted by tirzepatide, and the GLP-1 pathway targeted by semaglutide — but unlike both of those, retatrutide remains investigational and not FDA-approved. Published comparative analyses suggest the triple-agonist class may produce more weight loss than tirzepatide, with a potentially higher rate of side effects, though a formal head-to-head trial is still underway. See our physician-reviewed tirzepatide vs. retatrutide comparison for a deeper look.
Is retatrutide safe?
Retatrutide is still being studied, so its full safety profile is not yet defined. The gastrointestinal effects seen with GLP-1-pathway medications — nausea, delayed stomach emptying, appetite suppression — also appear with this class, and rarer effects are still being characterized across the Phase 3 program. This is exactly why it is not approved or available as a prescription, and why any decision about weight-loss therapy belongs with a physician after an evaluation — not a web page or a checkout cart.
How much does retatrutide cost in Las Vegas?
Retatrutide itself has no legal price as a prescription because it is not FDA-approved and cannot be dispensed. What does have a price is physician-guided care: at LiveNow Longevity, an evaluation with Dr. Kamen is $88 and is applied toward your plan if you continue, with FDA-approved GLP-1/GIP medication billed at pharmacy pass-through cost and no markup. Your real monthly number is reviewed with you before you commit.
Is retatrutide available in Las Vegas or near me?
No — retatrutide cannot be dispensed as a standard prescription while it remains investigational and not FDA-approved, in Las Vegas, Henderson, or anywhere else. What is available at LiveNow Longevity is physician-supervised medical weight loss using FDA-approved medications, plus an honest, up-to-date conversation about where retatrutide stands. Bring your questions to your evaluation.
How does retatrutide work?
Retatrutide engages three metabolic pathways at once — GLP-1 and GIP (which influence appetite, blood sugar, and how the body handles food) plus glucagon (which affects energy expenditure and liver fat). Targeting all three is the reason this class is being studied so closely. Any decision about therapy is made by a physician after evaluation, not from a web page.
Should I wait for retatrutide or start an FDA-approved GLP-1 now?
That depends on your goals, labs, and timeline, and it is a medical decision — not a marketing one. FDA-approved options like semaglutide and tirzepatide are available now, after an evaluation, and are effective for many people. If you are interested in retatrutide specifically, Dr. Kamen can tell you honestly where it stands and whether waiting makes sense for you. Start with the $88 evaluation.
Selected Research
- Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526. (Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial).
- Retatrutide for obesity, OSA and knee osteoarthritis: rationale and design of the TRIUMPH registrational program. Diabetes Obes Metab. 2026. (PMC12673447).
- Comparative efficacy and safety of tirzepatide vs retatrutide in weight loss: a network meta-analysis. J Endocr Soc. 2025. (PMC12544991).
- Müller TD, et al. Mol Metab. 2019;30:72-130. (Glucagon-like peptide 1 (GLP-1): physiology, satiety, and metabolism).
Background mechanistic and trial-design sources only. Not a treatment claim. Individual results vary; retatrutide is investigational and not FDA-approved.
Physician-Led in Las Vegas
Have questions about retatrutide? Ask us in person.
The clearest, most current answers about retatrutide come from a conversation with a physician — not a web page or a checkout cart. Start with an $88 evaluation, and Dr. Kamen will walk through where retatrutide stands and which FDA-approved options like tirzepatide fit your goals. See also our tirzepatide vs. retatrutide comparison.
Ready to start your longevity care?
Book your $88 evaluation with Dr. Kamen today, online, by phone, or by text.
Prefer to talk? Call (702) 808-2650 or text us to book.
Also serving Henderson — or explore semaglutide weight loss in Las Vegas.